Treating pulmonary hypertension depends entirely on what’s causing it. The World Health Organization classifies this condition into five distinct groups, each with a different underlying problem and a different treatment strategy. For the most common treatable form, pulmonary arterial hypertension (Group 1), current guidelines recommend starting most patients on two medications simultaneously rather than one. Beyond medication, treatment can include oxygen therapy, surgical procedures, lifestyle changes, and in some cases, lung transplantation.
Why the Cause Determines the Treatment
Pulmonary hypertension isn’t a single disease. It’s high blood pressure in the arteries of your lungs, and it can develop for very different reasons. The five WHO groups reflect this:
- Group 1: Pulmonary arterial hypertension (PAH), where the small arteries in the lungs narrow and stiffen on their own
- Group 2: Caused by left-sided heart disease, the most common form overall
- Group 3: Caused by chronic lung disease or low oxygen levels
- Group 4: Caused by old blood clots that never fully dissolved in the lung arteries (chronic thromboembolic pulmonary hypertension, or CTEPH)
- Group 5: Caused by unclear or overlapping mechanisms
This distinction matters because the targeted medications developed specifically for pulmonary hypertension only work for certain groups. If your pulmonary hypertension is caused by left-sided heart failure (Group 2), for instance, the priority is treating that heart failure, not adding PAH-specific drugs. If it’s caused by lung disease (Group 3), treating the underlying condition and providing supplemental oxygen are the main approaches. Using the wrong treatment strategy can actually cause harm, which is why getting an accurate diagnosis and group classification is the essential first step.
Medications for Pulmonary Arterial Hypertension
Group 1 PAH has the most developed medication toolkit. These drugs work by relaxing and opening the narrowed lung arteries, reducing the strain on the right side of your heart. They target three main biological pathways, and doctors typically combine drugs from different pathways for a stronger effect.
Endothelin Receptor Antagonists
Your body produces a substance called endothelin that constricts blood vessels. In PAH, there’s too much of it. Endothelin receptor antagonists (drugs like bosentan, ambrisentan, and macitentan) block this signal, allowing the lung arteries to relax. These are oral medications taken daily and form one half of the recommended starting combination for most newly diagnosed patients.
PDE-5 Inhibitors
These drugs boost the effect of nitric oxide, a natural molecule that widens blood vessels. Sildenafil and tadalafil are the two main options, both taken orally. Together with an endothelin receptor antagonist, they make up the dual-combination therapy that the 2022 European Society of Cardiology and European Respiratory Society guidelines recommend as the standard initial treatment for patients at low or intermediate risk. This combination improves symptoms, exercise capacity, and cardiac stress markers, and reduces hospitalizations compared to starting with a single drug.
Prostacyclin Pathway Therapies
Prostacyclin is another natural substance that relaxes blood vessels and prevents clotting. For patients who aren’t improving enough on oral medications, prostacyclin-based drugs offer a more intensive option, though they come with more demanding delivery methods.
Epoprostenol requires continuous intravenous infusion through a specialized catheter and portable pump, 24 hours a day. Treprostinil can be delivered the same way or through a small catheter under the skin of the abdomen. Inhaled versions are also available: iloprost requires nebulizer treatments 6 to 9 times daily, while inhaled treprostinil needs only 4 treatments per day with a specialized nebulizer device. The continuous infusion forms are the most potent but require significant commitment to maintain the pump and catheter system.
Sotatercept: A Newer Approach
The newest class of PAH treatment works differently from all the others. Instead of relaxing blood vessels, sotatercept targets the abnormal cell growth that thickens and stiffens the lung arteries in the first place. It’s a fusion protein given by injection that traps specific growth signals involved in this remodeling process. In a major phase 3 trial published in the New England Journal of Medicine, patients receiving sotatercept improved their six-minute walk distance by about 34 meters over 24 weeks, compared to just 1 meter in the placebo group. That 40-meter difference is clinically meaningful for people whose daily activity is severely limited by breathlessness.
Combination Therapy as the Standard
One of the biggest shifts in PAH treatment over the past decade is the move toward starting with two drugs from the outset rather than adding them one at a time. For newly diagnosed patients at low or intermediate risk, guidelines now recommend initial dual-combination therapy with an endothelin receptor antagonist and a PDE-5 inhibitor. Initial oral triple-combination therapy is not currently recommended due to lack of evidence supporting it, but doctors may add a third drug (often a prostacyclin pathway therapy) later if the first two aren’t enough.
This layered approach reflects how serious PAH is. Even with modern treatments, survival data from registry studies show 1-year, 3-year, and 5-year survival estimates of roughly 92%, 75%, and 66%. Early aggressive treatment aims to improve those numbers by preventing the right side of the heart from failing under the sustained pressure.
Treating CTEPH: Surgery and Medication
Group 4 pulmonary hypertension, caused by chronic blood clots in the lung arteries, has its own distinct treatment. Pulmonary endarterectomy, a surgery that physically removes the organized clot material from the artery walls, is the standard treatment and the only potentially curative option. Every patient with CTEPH should be evaluated at an experienced surgical center using high-quality imaging to determine whether the clots are in a location that can be reached surgically.
For patients whose clots are too far into the small branches to be removed surgically, or who still have elevated pressures after surgery, riociguat is an approved medication. It works along the nitric oxide pathway (similar to PDE-5 inhibitors but through a different mechanism) and was shown in a large randomized trial to improve exercise capacity and reduce lung artery pressure in inoperable CTEPH patients.
Oxygen Therapy
When blood oxygen levels drop below a certain threshold, supplemental oxygen becomes part of the treatment plan. The general target is keeping your oxygen saturation above 90% both at rest and during physical activity. For patients with PAH or CTEPH whose saturation dips to 90% or below at rest or during exercise despite being on optimized medications, long-term oxygen therapy is considered. The flow rate is individually titrated to keep levels in the safe range.
Oxygen therapy doesn’t treat the underlying disease, but it reduces the strain on your heart and can ease breathlessness during everyday activities. Some people need it only during exercise or sleep, while others require it continuously.
Surgical Options When Medications Aren’t Enough
For patients who continue to deteriorate despite maximum medical therapy, two procedural options exist. Atrial septostomy is a palliative procedure performed in a catheterization lab under local anesthesia. A small hole is created between the two upper chambers of the heart using a needle and then gradually widened with balloon catheters. This allows some blood to bypass the struggling right side of the heart, improving blood flow to the body at the cost of slightly lower oxygen levels (the goal is keeping saturation between 80% and 85% after the procedure). Patients who undergo atrial septostomy typically experience notable improvement in symptoms and exercise capacity, though breathlessness often persists. This procedure should only be performed at specialized centers with extensive experience managing PAH.
Lung transplantation (or combined heart-lung transplantation) remains the final option for patients who are not responding to any available therapy. It is not a cure in the traditional sense, as it comes with lifelong immunosuppression and its own set of risks, but it can offer meaningful survival and quality of life for patients who have exhausted other options.
Daily Lifestyle Management
Medications and procedures are only part of managing pulmonary hypertension. What you do every day has a real impact on how you feel and how stable your condition stays.
Fluid and sodium management are central to preventing the fluid overload that strains your right heart. Most pulmonary hypertension specialists recommend limiting sodium to 2 grams per day and fluid intake to 2 liters (about 8 cups) per day. Sticking to these limits requires learning to read food labels carefully, since processed and restaurant foods often contain far more sodium than people expect. Daily weighing helps you catch fluid retention early: a sudden gain of 2 or more pounds in a day, or a steady upward trend over several days, typically means you’re retaining fluid and need to adjust.
Exercise is beneficial but needs to be approached carefully. Supervised exercise rehabilitation programs have shown improvements in exercise capacity and quality of life for PAH patients. The key is avoiding activities that cause significant breathlessness, dizziness, or chest pain. Walking, light cycling, and gentle resistance training are generally well tolerated, while heavy lifting and intense exertion that involve straining (like the Valsalva maneuver) can dangerously spike lung artery pressure. Working with a physiotherapist who understands pulmonary hypertension is the safest way to build an exercise routine.